Related Experiment Videos
Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong
J Chau1, B M Cheung, S M McGhee
1Department of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|January 5, 2002
Summary
Secondary prevention with pravastatin is a cost-effective strategy for Hong Kong patients with coronary heart disease. This analysis of the CARE study provides key cost per quality-adjusted life year gained figures for healthcare resource allocation.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Coronary heart disease (CHD) poses a significant burden on healthcare systems.
- Secondary prevention strategies are crucial for managing patients post-myocardial infarction (MI).
- Pravastatin has demonstrated efficacy in reducing cardiovascular events.
Purpose of the Study:
- To evaluate the cost-effectiveness of pravastatin for secondary prevention in Hong Kong patients with CHD.
- To determine the cost per quality-adjusted life year (QALY) gained from pravastatin therapy.
- To inform healthcare resource allocation decisions for CHD management in Hong Kong.
Main Methods:
- Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed.
- Data were based on published results from the Pravastatin Pooling Project (CARE study).
- Analyses included costs per life saved, event prevention, procedure prevention, and QALY gained.
Main Results:
- The cost per life saved was HK$4,442,350.
- The cost per fatal or non-fatal cardiac event prevented was HK$1,146,413.
- Net cost per QALY gained was HK$73,218 and HK$65,280 using two models.
Conclusions:
- Pravastatin therapy for secondary prevention in CHD patients is a potentially cost-effective intervention in Hong Kong.
- Findings can guide healthcare resource prioritization for CHD.
- Results should be considered alongside alternative CHD interventions.